What Cowen analyst Tara Bancroft called an “exciting” year ahead for Day One Biopharmaceuticals Inc. will be shared by Servier SAS, after the French firm agreed to pay $21.50 per share to acquire Day One in a deal that notched an equity value of about $2.5 billion. Read More
Investors looking for midteen percentage weight loss findings in Zealand Pharma A/S’s phase II study of once-weekly amylin analogue petrelintide were clearly disappointed by the actual 10.7% mean body weight reduction, as shares (Copenhagen:ZEAL) fell 36% March 6. But from the company’s standpoint, the combination of efficacy and safety data from the Zupreme-1 study bode well for a phase III trial expected to start later this year. Read More
Japan has approved the world’s first therapies derived from induced pluripotent stem cells (iPSCs), marking a major milestone for regenerative medicine and, potentially, a turning point in treating Parkinson’s disease. Read More
Pricing shares at $20 each, below the intended price range, insulin delivery company Minimed Group Inc. debuted with an IPO on Nasdaq March 6, raising $560 million. The company offered a total of 28 million shares, which would have brought the Northridge, Calif.-based company $742 million in gross proceeds if the IPO had priced at the midpoint of the $25-to-$28 price range disclosed in February. Read More
One year on from establishing the baseline on female representation in the U.K. biotech industry, the latest survey shows the “dial is stuck.” Since the first report, representation at the CEO level has crept from 18.3% to 18.7%. That is “a marginal gain that signals a plateau at a time when we need a breakthrough,” said Jane Wall, managing director of the U.K. Bioindustry Association, which compiled the statistics. Read More
Biopharma financings totaled $16.78 billion in the first two months of 2026, about an 81% year-over-year rise from $9.28 billion in January to February 2025. While still below the outsized $33.29 billion recorded in the same period of 2024, and $24.37 billion in 2021, the early 2026 total significantly outpaces the more subdued levels seen in 2022 ($7.48 billion) and 2023 ($7.66 billion). Read More
The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security. Read More
Perimeter Medical Imaging AI Inc. secured FDA premarket approval for Claire, its AI-powered imaging device which detects difficult-to-see cancer during breast-conserving surgery. Claire combines AI with wide-field optical coherence tomography to provide surgeons with high-resolution, real-time views of excised tumor margins, to reduce the need for re-operations. Read More
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic disruption may drive Alzheimer’s disease pathology. Read More
New hires and promotions in the biopharma and med-tech industries, including: Arcutis, Avalyn, Coloplast, Invivyd, Pacbio, Sanofi, Swarm, Tango, Vera, Xylocor, Zevra. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Akeso, Biogen, Bioxcel, ITM, Medicus, Parabilis, Response, Stoke. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Bcworld, Carisma, Charles River, Daiichi Sankyo, Gaia, Grünenthal, Flo, Immunis, Imperial, Liberate, Nano-x, Novigenix, Oxipit, Sectra, Therna, Toray. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Airiver, Becton Dickinson, Biomerica, Drug Farm, Hansa, Hemab, Pepgen, Perimeter. Read More
